E

    Evaxion Biotech AS (EVAX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.00
    -0.01 (-0.33%)

    Market Cap: $25.10M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(16/24)
    Avg Surprise
    -185.27%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.01
    Range$-0.01 - $-0.01
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.01+0.0%
    60d ago$-0.01+0.0%
    30d ago$-0.01+0.0%
    7d ago$-0.01+0.0%
    Current$-0.01
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Dec 31, 2026
    EPS Consensus$0.21
    Range$0.21 - $0.21
    2 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.21---
    Sep 26EST
    		-$-0.01---
    Jun 26
    		$-0.50$-0.01-4900.00%Miss+50.0%
    Mar 26
    		$-0.01$-0.01+0.00%Beat+98.0%
    Dec 25
    		$-0.01$-0.01+0.00%Beat+85.7%
    Sep 25
    		$0.01$-0.01+200.00%Beat+105.0%
    Jun 25
    		$-1.00$-0.58-72.41%Miss+83.3%
    Mar 25
    		$-0.50$-0.70+28.57%Beat-266.7%
    Dec 24
    		$-0.07N/A+53.33%Beat+99.1%
    Sep 24
    		$-0.20N/A+66.67%Beat+98.1%
    Jun 24
    		$-6.00$-3.50-71.43%Miss+42.9%
    Mar 24
    		$0.30$-0.56+153.57%Beat+102.1%
    Dec 23
    		$-8.00$-8.00+0.00%Beat-175.9%
    Sep 23
    		$-10.50$-9.75-7.69%Miss+12.5%
    Jun 23
    		$-10.50$-10.75+2.33%Beat+12.5%
    Mar 23
    		$-14.50$-13.17-10.10%Miss-45.0%
    Dec 22
    		$-2.90$-2.63-10.27%Miss-1060.0%
    Nov 22
    		$-12.00$-17.00+29.41%Beat+38.5%
    Sep 22
    		$-12.00$-13.33+9.98%Beat+11.1%
    Jun 22
    		$-10.00$-15.00+33.33%Beat+44.4%
    Mar 22
    		$-0.25$-0.33+24.24%Beat+97.8%
    Dec 21
    		$-19.50$-15.00-30.00%Miss-10163.2%
    Sep 21
    		$-13.50$-17.25+21.74%Beat-36.3%
    Jun 21
    		$-18.00$-14.75-22.03%Miss-137.3%
    Mar 21
    		$-11.50$-16.50+30.30%Beat-78.1%
    Dec 20
    		$-0.19$-0.25+24.00%Beat+97.4%
    Sep 20
    		$-9.90N/AN/ABeat-
    Jun 20
    		$-7.58N/AN/ABeat-
    Mar 20
    		$-6.46N/AN/ABeat-
    Dec 19
    		$-7.33N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-5.88EV/EBITDA-0.59x
    Price/FCF-0.07xFCF Yield-1404.79%
    Profitability
    Profit Margin-115.50%Operating Margin-116.00%
    ROE-109.90%ROIC-118.22%
    Financial Health
    Debt/Equity0.06xInterest Coverage-4.27x
    Current Ratio5.06xQuick Ratio5.06x
    Trading Statistics
    Beta0.25Avg Volume543.88K
    52-Week High$12.1552-Week Low$2.52

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.20
    SMA 20$3.15
    SMA 50$3.12
    SMA 200$3.98
    EMA 10$3.15
    EMA 20$3.14
    EMA 50$3.22
    EMA 200$3.62

    MACD

    Line: 0.01Signal: 0.02Hist: -0.01

    ADX

    ADX: 26.9+DI: 19.3-DI: 18.2

    Aroon & PSAR

    Aroon Up72.0
    Aroon Down20.0
    PSAR$3.64

    Bollinger Bands

    Upper Band$3.42
    Lower Band$2.87
    %B Position1738%(Upper)
    Band Width0.23

    RSI (14-Day)

    Neutral
    42.6

    Momentum Oscillators

    Stoch %K27.6
    Stoch %D38.8
    Williams %R-79.0
    ROC (10d)-4.2%
    Momentum-0.13
    CCI (20d)-91.0
    MFI (14d)96.2

    Volatility Measures

    ATR (14d)$0.24(7.9%)
    StdDev (20d)0.14
    Hist Vol50.0%(High)

    Volume Flow

    VWAP$2.99
    OBV86.1M
    AD Line34.2M
    CMF (20d)0.075

    Volume Metrics

    Avg Vol (20d)570.7K
    Vol Ratio0.2x(Low)
    VWMA (20d)$3.20

    Pivot Points

    R3$3.26
    R2$3.21
    R1$3.11
    Pivot Point$3.06
    S1$2.96
    S2$2.91
    S3$2.81

    Advanced Oscillators

    TSI2.33
    Ultimate Osc42.4
    KST59.45

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$22,040$7.49M$37,000$122,000$122,000$3.02M$154,000$50,881$73,000$0
    Cost of RevenueN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
    Gross ProfitN/AN/A$-7,529,000$7.49M$37,000$122,000N/A$3.02M$154,000$50,881$73,000N/A
    Operating Expenses$3.84M$3.82M$4.05M$4.47M$4.38M$3.87M$4.15M$4.75M$4.74M$4.44M$4.44M$5.76M
    R&D$2.33M$2.30M$2.56M$3.09M$2.17M$2.16M$2.25M$2.61M$2.75M$2.83M$2.30M$2.83M
    SG&A$0$1.52M$1.19M$1.38M$2.21M$1.71M$1.59M$2.13M$1.98M$1.61M$1.86M$2.93M
    Operating Income$-3,840,529$-3,819,000$-4,052,000$3.02M$-4,340,000$-3,868,000$-4,024,000$-1,731,000$-4,581,000$-4,385,760$-4,364,000$-5,762,000
    Interest Income$0$305,000$5.43M$2.69M$30,000$2.49M$5.67M$84,000$41,000$5.62M$250,000$72,000
    Interest Expense$160,771$332,000$1.12M$1.36M$241,000$397,000$1.70M$385,211$225,000$246,000$168,000$182,000
    Income Before Tax$-3,927,406$-3,845,000$-6,173,000$4.35M$-5,026,000$-1,772,000$-3,904,000$-2,031,000$-6,397,000$973,726$-4,700,000$-5,872,000
    Income Tax Expense$-203,709$-216,000$-256,000$-265,000$-195,000$-192,000$0$-96,000$-199,000$-217,492$-177,000$-194,000
    Net Income$-3,723,696$-3,629,000$-5,918,000$4.62M$-4,831,000$-1,580,000$-3,629,000$-1,935,000$-6,198,000$1.19M$-4,523,000$-5,678,000
    EBITDA$-3,840,529$-3,513,000$-8,285,000$5.71M$-4,785,000$-1,375,000N/A$-1,647,000$-6,172,000$1.22M$-4,474,000$-5,490,000
    EBITN/AN/A$-8,814,262$3.02MN/A$-5,607,000N/A$-1,647,000$-4,581,000$1.18M$-4,589,000$-5,690,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about EVAX

    News

    Evaxion Biotech A/S (EVAX) Stock News Today

    This article provides recent news for Evaxion Biotech A/S (EVAX), including its current stock price, market cap, and a link to its latest earnings call transcript. The company reported $14M in cash and provided an update on EVX-01 during its Q2 2026 earnings. The article serves as a brief overview of recent developments for EVAX investors.

    TradingKey•8/23/26•
    Neutral

    Analysts’ Top Healthcare Picks: Evaxion Biotech (EVAX), Ultragenyx Pharmaceutical (RARE)

    This article highlights bullish analyst ratings for two healthcare companies: Evaxion Biotech (EVAX) and Ultragenyx Pharmaceutical (RARE). An H.C. Wainwright analyst reiterated a Buy rating for Evaxion Biotech with a $16 price target, while a Morgan Stanley analyst maintained a Buy rating for Ultragenyx Pharmaceutical with a $74 price target. Both companies received strong analyst consensus ratings, indicating potential upside for investors.

    The Globe and Mail•8/22/26•
    Bullish

    Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX) and Boston Scientific (BSX)

    Two healthcare companies, Evaxion Biotech (EVAX) and Boston Scientific (BSX), have received bullish ratings from analysts. Evaxion Biotech was reiterated with a Buy rating and a $9.00 price target by Lake Street, while Boston Scientific also received a Buy rating and a $60.00 price target from Jefferies. Both companies show significant upside potential based on current analyst consensus.

    The Globe and Mail•8/22/26•
    Bullish

    EVAXION BIOTECH ($EVAX) Releases Q2 2026 Earnings

    This article announces that Evaxion Biotech ($EVAX) has released its Q2 2026 earnings report. Further details regarding the financial performance would be found within the full earnings document.

    Moomoo•8/21/26•
    Neutral

    Evaxion Expands Pipeline with EVX-05, an AI-Designed Off-the-Shelf Glioblastoma Vaccine

    Evaxion has added EVX-05, an AI-designed, off-the-shelf therapeutic vaccine for glioblastoma, to its pipeline, while discontinuing the EVX-03 program to refocus R&D efforts. This new vaccine targets antigens derived from endogenous retroviruses, which are overexpressed in cancer cells, making them ideal for an off-the-shelf approach. The company is collaborating with Duke University School of Medicine and expects to advance EVX-05 towards initial clinical testing without impacting its current cash runway.

    BioPharm International•8/18/26•
    Bullish

    Frequently Asked Questions About EVAX

    Does EVAX pay dividends?
    Evaxion Biotech AS (EVAX) does not currently pay a regular dividend.
    What is EVAX's market cap?
    Evaxion Biotech AS (EVAX) has a market capitalization of $25.10M with a current stock price of $3.00.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In